Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Prognostic consequences of implementing cancer patient pathways in Denmark: a comparative cohort study of symptomatic cancer patients in primary care

Authors: Henry Jensen, Marie Louise Tørring, Peter Vedsted

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Cancer Patient Pathways (CPPs) were introduced in 2000–2015 in several European countries, including Denmark, to reduce the time to diagnosis and treatment initiation and ultimately improve patient survival. Yet, the prognostic consequences of implementing CPPs remain unknown for symptomatic cancer patients diagnosed through primary care.
We aimed to compare survival and mortality among symptomatic patients diagnosed through a primary care route before, during and after the CPP implementation in Denmark.

Methods

Based on data from the Danish Cancer in Primary Care (CaP) Cohort, we compared one- and three-year standardised relative survival (RS) and excess hazard ratios (EHRs) before, during and after CPP implementation for seven types of cancer and all combined (n = 7725) by using life-table estimation and Poisson regression. RS estimates were standardised according to the International Cancer Survival Standard (ICSS) weights. In addition, we compared RS and EHRs for CPP and non-CPP referred patients to consider potential issues of confounding by indication.

Results

In total, 7725 cases were analysed: 1202 before, 4187 during and 2336 after CPP implementation. For all cancers combined, the RS3years rose from 45% (95% confidence interval (CI): 42;47) before to 54% (95% CI: 52;56) after CPP implementation. The excess mortality was higher before than after CPP implementation (EHR3years before vs. after CPP = 1.35 (95% CI: 1.21;1.51)). When comparing CPP against non-CPP referred patients, we found no statistically significant differences in RS, but we found lower excess mortality among the CPP referred (EHR1year CPP vs. non-CPP = 0.86 (95% CI: 0.73;1.01)).

Conclusion

We found higher relative survival and lower mortality among symptomatic cancer patients diagnosed through primary care after the implementation of CPPs in Denmark. The observed changes in cancer prognosis could be the intended consequences of finding and treating cancer at an early stage, but they may also reflect lead-time bias and selection bias. The finding of a lower excess mortality among CPP referred compared to non-CPP referred patients indicates that CPPs may have improved the cancer prognosis independently.
Literature
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
2.
Storm HH, Kejs AM, Engholm G. Improved survival of Danish cancer patients 2007–2009 compared with earlier periods. Dan Med Bull. 2011;58:A4346.PubMed
3.
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377:127–38.CrossRefPubMedPubMedCentral
4.
5.
Storm HH, Engholm G, Hakulinen T, Tryggvadottir L, Klint A, Gislum M, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999–2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010;49:532–44.CrossRefPubMed
6.
Vedsted P, Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. Br J Gen Pract. 2011;61:e508–12.CrossRefPubMedPubMedCentral
7.
Prades J, Espinas JA, Font R, Argimon JM, Borras JM. Implementing a Cancer Fast-track Programme between primary and specialised care in Catalonia (Spain): a mixed methods study. Br J Cancer. 2011;105:753–9.CrossRefPubMedPubMedCentral
8.
Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians-A national Danish project. Health Policy. 2012;105:65–70.CrossRefPubMed
9.
10.
Toustrup K, Lambertsen K, Birke-Sorensen H, Ulhoi B, Sorensen L, Grau C. Reduction in waiting time for diagnosis and treatment of head and neck cancer - a fast track study. Acta Oncol. 2011;50:636–41.CrossRefPubMed
11.
Lyhne NM, Christensen A, Alanin MC, Bruun MT, Jung TH, Bruhn MA, et al. Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002. Eur J Cancer. 2013;49:1627–33.CrossRefPubMed
12.
Vallverdu-Cartie H, Comajuncosas-Camp J, Orbeal-Saenz RA, Lopez-Negre JL, Gris Garriga PJ, Jimeno-Fraile J, et al. Results of implementation of a fast track pathway for diagnosis of colorectal cancer. Rev Esp Enferm Dig. 2011;103:402–7.CrossRefPubMed
13.
Valentin-Lopez B, Ferrandiz-Santos J, Blasco-Amaro JA, Morillas-Sainz JD, Ruiz-Lopez P. Assessment of a rapid referral pathway for suspected colorectal cancer in Madrid. Fam Pract. 2012;29:182–8.CrossRefPubMed
14.
Department of Health. The NHS cancer plan. London: Department of Health; 2000.
15.
Guzman Laura KP, Bolibar RI, Alepuz MT, Gonzalez D, Martin M. Impact on patient care time and tumor stage of a program for fast diagnostic and treatment of colorectal cancer. Rev Esp Enferm Dig. 2011;103:13–9.CrossRefPubMed
16.
Hansen RP, Vedsted P, Sokolowski I, Sondergaard J, Olesen F. Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv Res. 2011;11:284.CrossRefPubMedPubMedCentral
17.
Larsen MB, Hansen RP, Hansen DG, Olesen F, Vedsted P. Secondary care intervals before and after the introduction of urgent referral guidelines for suspected cancer in Denmark: a comparative before-after study. BMC Health Serv Res. 2013;13:348.CrossRefPubMedPubMedCentral
18.
Zafar A, Mak T, Whinnie S, Chapman MA. The 2-week wait referral system does not improve 5-year colorectal cancer survival. Color Dis. 2012;14:e177–80.CrossRef
19.
Currie AC, Evans J, Smith NJ, Brown G, Abulafi AM, Swift RI. The impact of the two-week wait referral pathway on rectal cancer survival. Color Dis. 2012;14:848–53.CrossRef
20.
Sugumaran A, Hurlay J, George P, Pye J. OC-025: Impact of urgent suspected cancer (USC) versus non-USC referral pathways on survival of upper GI cancers. Gut. 2011;60(Suppl I):A13–4. 10-9-2015CrossRef
21.
Neal RD, Allgar VL, Ali N, Leese B, Heywood P, Proctor G, et al. Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. Br J Gen Pract. 2007;57:212–9.PubMedPubMedCentral
22.
Schneider C, Bevis PM, Durdey P, Thomas MG, Sylvester PA, Longman RJ. The association between referral source and outcome in patients with colorectal cancer. Surgeon. 2013;11:141–6.CrossRefPubMed
23.
Sharpe D, Williams RN, Ubhi SS, Sutton CD, Bowrey DJ. The “two-week wait” referral pathway allows prompt treatment but does not improve outcome for patients with oesophago-gastric cancer. Eur J Surg Oncol. 2010;36:977–81.CrossRefPubMed
24.
Palser TR, Cromwell DA, Hardwick RH, Riley SA, Greenaway K, van der Meulen JH. Impact of route to diagnosis on treatment intent and 1-year survival in patients diagnosed with oesophagogastric cancer in England: a prospective cohort study. BMJ Open. 2013;3:e002129
25.
26.
Allgar VL, Neal RD, Ali N, Leese B, Heywood P, Proctor G, et al. Urgent GP referrals for suspected lung, colorectal, prostate and ovarian cancer. Br J Gen Pract. 2006;56:355–62.PubMedPubMedCentral
27.
28.
Jensen H, Torring ML, Larsen MB, Vedsted P. Existing data sources for clinical epidemiology: Danish Cancer in Primary Care (CaP) cohort. Clin Epidemiol. 2014;6:237–46.CrossRefPubMedPubMedCentral
29.
Pedersen KM, Andersen JS, Sondergaard J. General practice and primary health care in Denmark. J Am Board Fam Med. 2012;25(Suppl 1):S34–8.CrossRefPubMed
30.
Danish National Board of Health. Aftale om gennemførelse af målsætningen om akut handling og klar besked til kræftpatienter [In Danish]. 12-10-2007. Accessed 31 July 2017.
31.
Mukai TO, Bro F, Pedersen KV, Vedsted P. Use of prostate-specific antigen testing. Ugeskr Laeger. 2010;172:696–700.PubMed
32.
Outzen M, Brasso K, Martinussen N, Christensen J, Tjonneland A, Friis S, et al. Prostate cancer in Denmark 1978-2009--trends in incidence and mortality. Acta Oncol. 2013;52:831–6.CrossRefPubMed
33.
Hjertholm P, Fenger-Gron M, Vestergaard M, Christensen MB, Borre M, Moller H, et al. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. Int J Cancer. 2015;136:435–42.CrossRefPubMed
34.
Jensen H, Tørring ML, Fenger-Gron M, Olesen F, Overgaard J, Vedsted P. Tumour stage and implementation of standardised cancer patient pathways: a comparative cohort study in general practice. Brit J Gen Pract. 2016;66:e434–43.CrossRef
35.
Danish National Board of Health. Det moderniserede Cancerregister - metode og kvalitet [The modernised Cancer Registry – methods and quality]. Copenhagen S: the Danish National Board of Health; 2009.
36.
37.
Deleuran T, Sogaard M, Froslev T, Rasmussen TR, Jensen HK, Friis S, et al. Completeness of TNM staging of small-cell and non-small-cell lung cancer in the Danish cancer registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):39–44.CrossRefPubMedPubMedCentral
38.
Ostenfeld EB, Froslev T, Friis S, Gandrup P, Madsen MR, Sogaard M. Completeness of colon and rectal cancer staging in the Danish Cancer Registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):33–8.CrossRefPubMedPubMedCentral
39.
Froslev T, Grann AF, Olsen M, Olesen AB, Schmidt H, Friis S, et al. Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):5–10.CrossRefPubMedPubMedCentral
40.
Holland-Bill L, Froslev T, Friis S, Olsen M, Harving N, Borre M, et al. Completeness of bladder cancer staging in the Danish Cancer Registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):25–31.CrossRefPubMedPubMedCentral
41.
42.
Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40:2307–16.CrossRefPubMed
43.
Jensen H, Torring ML, Olesen F, Overgaard J, Fenger-Gron M, Vedsted P. Diagnostic intervals before and after implementation of cancer patient pathways - a GP survey and registry based comparison of three cohorts of cancer patients. BMC Cancer. 2015;15:308.CrossRefPubMedPubMedCentral
44.
Neal RD, Din NU, Hamilton W, Ukoumunne OC, Carter B, Stapley S, et al. Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database. Br J Cancer. 2014;110:584–92.CrossRefPubMed
45.
Jensen H, Vedsted P. Exploration of the possible effect on survival of lead-time associated with implementation of cancer patient pathways among symptomatic first-time cancer patients in Denmark. Cancer Epidemiol. 2017;49:195–201.CrossRefPubMed
46.
Chohan DP, Goodwin K, Wilkinson S, Miller R, Hall NR. How has the ‘two-week wait’ rule affected the presentation of colorectal cancer? Color Dis. 2005;7:450–3.CrossRef
47.
Forrest LF, Adams J, White M, Rubin G. Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: population-based, data-linkage study. Br J Cancer. 2014;111:1843–51.CrossRefPubMedPubMedCentral
48.
Nguyen-Nielsen M, Froslev T, Friis S, Borre M, Harving N, Sogaard M. Completeness of prostate cancer staging in the Danish Cancer Registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):17–23.CrossRefPubMedPubMedCentral
49.
Ording AG, Nielsson MS, Froslev T, Friis S, Garne JP, Sogaard M. Completeness of breast cancer staging in the Danish Cancer Registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):11–6.CrossRefPubMedPubMedCentral
50.
51.
Walters S, Benitez-Majano S, Muller P, Coleman MP, Allemani C, Butler J, et al. Is England closing the international gap in cancer survival? Br J Cancer. 2015;113:848–60.CrossRefPubMedPubMedCentral
52.
Jensen KH, Maina PJ. Cancer pathways are associated with improved long-term survival. Dan Med J. 2015;61:A5000.
53.
Guldbrandt LM, Fenger-Gron M, Rasmussen TR, Jensen H, Vedsted P. The role of general practice in routes to diagnosis of lung cancer in Denmark: a population-based study of general practice involvement, diagnostic activity and diagnostic intervals. BMC Health Serv Res. 2015;15:21.CrossRefPubMedPubMedCentral
54.
Jakobsen E, Rasmussen TR, Green A. Mortality and survival of lung cancer in Denmark: results from the Danish Lung Cancer Group 2000–2012. Acta Oncol. 2016:1–8.
55.
Jensen H, Torring ML, Olesen F, Overgaard J, Vedsted P. Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study. BMC Cancer. 2014;14:636.CrossRefPubMedPubMedCentral
56.
Danish National Board of Health. National Cancer Plan II • Denmark National Board of Health recommendations for improving cancer healthcare services. Copenhagen: The National Board of Health; 2005.
57.
Ottesen B, Iversen MG, Kehlet H. Surgical treatment for ovarian cancer in Denmark 2004–2007. Ugeskr Laeger. 2009;171:217–20.PubMed
58.
Lykke J, Roikjaer O, Jess P. The majority of surgical departments adhere to national Danish guidelines for surveillance after colorectal cancer surgery. Dan Med J. 2013;60:A4664.PubMed
59.
Jensen LS, Nielsen H, Mortensen PB, Pilegaard HK, Johnsen SP. Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol. 2010;36(Suppl 1):S50–4.CrossRefPubMed
60.
Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery. 2002;131:6–15.CrossRefPubMed
61.
Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. In: Br J Cancer; 2015;112(Suppl 1):S92–107.PubMedPubMedCentral
62.
Torring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: A cohort study in primary care. Eur J Cancer. 2013;49:2187–98.CrossRefPubMed
63.
Torring ML, Frydenberg M, Hamilton W, Hansen RP, Lautrup MD, Vedsted P. Diagnostic interval and mortality in colorectal cancer: U-shaped association demonstrated for three different datasets. J Clin Epidemiol. 2012;65:669–78.CrossRefPubMed
64.
Torring ML, Frydenberg M, Hansen RP, Olesen F, Hamilton W, Vedsted P. Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer. 2011;104:934–40.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic consequences of implementing cancer patient pathways in Denmark: a comparative cohort study of symptomatic cancer patients in primary care
Authors
Henry Jensen
Marie Louise Tørring
Peter Vedsted
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3623-8

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Study protocol

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study)

Research article

Prospective study of 11C–methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment

Research article

Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study

Case report

Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report

Research article

Smoking and alcohol cessation intervention in relation to radical cystectomy: a qualitative study of cancer patients’ experiences

Research article

Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits